Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment

Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment

IMPORTANCEThe practice of genetic testing for hereditary breast and/or ovarian cancer (HBOC) is rapidly evolving owing to the recent introduction of multigene panels.While these tests may identify 40% to 50% more individuals with hereditary cancer gene mutations than does testing for BRCA1/2 alone,...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Andrea Desmond, Allison W. Kurian, Michele Gabree, Meredith Mills, Michael J. Anderson, Yuya Kobayashi, Nora Horick, Shan Yang, Kristen M. Shannon, Nadine Tung, James M. Ford, Stephen E. Lincoln, Leif W. Ellisen
Médium: Artigo
Jazyk:angličtina
Vydáno: 2015
On-line přístup:https://doi.org/10.1001/jamaoncol.2015.2690
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Internet

https://doi.org/10.1001/jamaoncol.2015.2690

Podobné jednotky